Seeking Alpha

Vivus sues Actavis

  • Vivus (VVUS +0.6%) files a lawsuit in the U.S. District Court for the District of New Jersey against Actavis' (ACT -1.1%) ANDA to market and sell a generic version of Qsymia.
  • Since Vivus filed its suit within 45 days of the certification notice, the court will automatically issue a 30-month stay of the FDA's approval decision (the stay could be shorter if the court finds that the Qsymia patents are invalid, unenforceable or not infringed).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector